Splice Bio

Gene therapy company from Barcelona based on technology developed in the Muir Lab at Princeton University.

The company is developing novel gene therapies based on its proprietary intein platform technology to treat patients that suffer from incurable genetic diseases. The company’s platform has the potential to address two existing limitations of adeno-associated viruses (AAVs), both by increasing the size of the cargo gene that can be delivered and by expanding the range of tissues that can be targeted.

TEAM

TYPE

Biotech; inteins for gene therapy.

WEBSITE

splice.bio

LOGO